Monobactams

Creative Biolabs offers advanced Monobactams-linker synthesis service with the most suitable linkers to boost your antibody-antibiotic conjugates (AACs) development project. With a rich knowledge ofchemosynthesis, linker-design and bio-conjugation, Creative Biolabs can design a most appropriate linker for the Monobactam you are interested in, and synthesize the compound in the most time and cost efficient way.

Monobactams

Monobactams is a subgroup of β-lactam antibiotics wherein the β-lactam ring is alone and not fused to another ring, in contrast to most other β-lactams. Monobactams are effective only against aerobic Gram-negative bacteria (e.g., Neisseria, Pseudomonas). At present, aztreonam is the unique commercially available monobactam antibiotic. Other types of monobactams include tigemonam, nocardicin A, and tabtoxin.

Fig.1 Chemical structures of β-lactam antibiotics. Monobactams antibiotics wherein the β-lactam ring are alone and not fused to another ring, compared with other β-lactams such as penicillins, cephalosporins and carbapenems. (Holly, 2017)

Mode of Action of Monobactams

Monobactams is one of the β-lactam antibiotics which possess the sterilization ability like any other β-lactam antibiotics. Bacteria are generally in the low permeability osmotic pressure environment, thus will spontaneously absorb moisture from the outside. To prevent the crack expansion because the cell is bibulous too much, a kind of material called peptidoglycan in bacterial cell wall synthesis is essential to resist bacterial spontaneously swell. Monobactams can inhibit the transformation of peptidoglycan-synthesis process of bacteria, resulting in bacteria loses the ability of resistance to osmotic pressure and burst. Peptidoglycan is essential, especially for gram-positive bacteria cell wall structural integrity. The synthesis of peptidoglycan in the final step is by catalyzed by penicillin-binding protein (also called transpeptidase).

Monobactams-based AACs

Monobactams antibiotics are payloads in AACs under development and evaluation. The specific monoclonal antibody harbors the capability of delivery the monobactams exclusively to the infection site to reduce normal tissues damage. In detail, upon antibody seizes the antigen of bacteria, AAC can be internalized via receptor-mediated endocytosis and the antibiotics payload is released to accomplish its cytotoxic effects. Monobactams and β-GlcNAc-WTA mAb can be combined together to generate a potential AAC. It is known that β-GlcNAc-WTA mAb is a humanized monoclonal antibody, distinctively targeting β-GlcNAc residues which is a special antigen on the ribitol phosphate units of wall teichoic acid of bacteria.

Fig.2 Delivery of cytotoxic antibiotics to infection sites by AACs. The monoclonal antibody component of an AAC selectively binds a bacterial antigen, resulting in internalization of the AAC-antigen complex through the process of receptor-mediated endocytosis. The AAC-antigen complex then traffics to lysosomal compartments and is degraded, releasing active cytotoxic antibiotics inside the cell. Free antibiotic causes bacterial cell death depending on the drug's mechanism of action. (Panowski, 2014)

Creative Biolabs has well-established chemosynthesis platform and experienced scientists to help you develop monobactams-linker complexes using a full range of customized linkers, and we also provide antibody conjugation service for your AAC development and we believe that our customized services will promote the success of your projects. Please feel free to contact us for more information and a detailed quote.

References:

1. Holly, L. (2017). “Extended Infusions of Beta-lactams in Pediatric Patients: The long and the short of it”. The University of Texas at Austin College of Pharmacy Pharmacotherapy Education and Research Center.
2. Panowski, S.; et al. (2014). "Site-specific antibody-drug conjugates for cancer therapy". Mabs, 6(1): 34-45.

For Research Use Only. NOT FOR CLINICAL USE.